A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
NCT07662213
This study is recruiting at 13 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Type 2 Diabetes Mellitus
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AstraZeneca
- Last updated on ClinicalTrials.gov
- October 22, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Research Site · Phoenix, AZ
California · 3
- Research Site · Encinitas, CA
- Research Site · Pomona, CA
- Research Site · Sacramento, CA
Florida · 2
- Research Site · Lake City, FL
- Research Site · Leesburg, FL
Iowa · 1
- Research Site · Ames, IA
Maryland · 1
- Research Site · Rockville, MD
Nevada · 1
- Research Site · Henderson, NV
North Carolina · 2
- Research Site · Morehead City, NC
- Research Site · Wilmington, NC
Texas · 2
- Research Site · Houston, TX
- Research Site · Sugar Land, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.